

RECEIVED

JAN 03 2003

TECH CENTER 1600/2900

1647
#02
JB
2/14/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: TAM
Assignee: OSTEOPHARM INC.
Application No.: 09/323,854
Filing Date: June 2, 1999
Title: BONE STIMULATING FACTOR
Art Unit: 1647
Examiner: David S. Romeo
Atty's Docket No.: 46913/00047

RECEIVED

JAN 06 2003

TECH CENTER 1600/2900

The Commissioner of Patents and Trademarks
Washington, D.C. 20331
U.S.A.

Dear Sir:

We enclose the following:

1. Information Disclosure Statement, letter of explanation.
2. Substitute form 1449A/PTO listing U.S. Patent Documents and Foreign Patent Documents (1 page, in duplicate), and copies of listed references.
3. Substitute form 1449A/PTO listing Other Documents (3 pages, in duplicate), and copies of listed references.
4. Check for \$180.00.

The official fee of \$180.00 required for consideration of the enclosed Information Disclosure Statement and references is enclosed. The Commissioner is requested to charge any other fee which may be required for the papers being filed with this letter, or credit any overpayment, to Account No. 02-2553.


Should any Patent Office Official want to telephone, the call should be made to John C. Hunt (Registration No. 36,424) at (416) 863-4344.

Yours very truly,

John C. Hunt
Registration No. 36,424

December 30, 2002
Date

BLAKE, CASSELS & GRAYDON LLP
Box 25, Commerce Court West
Toronto, Ontario
M5L 1A9
Canada



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: TAM
Assignee: OSTEOPHARM INC.
Application No.: 09/323,854
Filing Date: June 2, 1999
Title: BONE STIMULATING FACTOR
Art Unit: 1647
Examiner: David S. Romeo
Atty's Docket No.: 46913/00047

The Commissioner of Patents and Trademarks
Washington, D.C. 20331
U.S.A.

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with 37 C.F.R. 1.56, the applicant wishes to call the attention of the Examiner to the references contained in an Information Disclosure Statement by Applicant (Substitute for form 1449A/PTO), enclosed herewith, in duplicate. Copies of the references are enclosed in accordance with 37 CFR 1.98.

With respect to the Vaughn reference, U17353 (C35), appended thereto is a fifth page showing the relationship between the beginning of sequences 1 to 4 shown therein, and SEQ ID NO:7 of United States Patent Application Serial No. 302,485, now United States Patent No. 5,786,327. SEQ ID NO:23 of the instant application corresponds to bases 124 to 231 of SEQ ID NO:7 of the '485 application.

The official fee of \$180.00 required for consideration of the enclosed Information Disclosure Statement and references is enclosed. The Commissioner is requested to charge any other fee which may be required for the papers being filed with this letter, or credit any overpayment, to Account No. 02-2553.

Should any Patent Office Official want to telephone, the call should be made to John C. Hunt (Registration No. 36,424) at (416) 863-4344.

Yours very truly,

John C. Hunt
Registration No. 36,424

December 30, 2002
Date

BLAKE, CASSELS & GRAYDON LLP
Box 25, Commerce Court West
Toronto, Ontario
M5L 1A9
Canada

01/02/2003 MBLANCO 00000025 09323854

01 FC:1806

180.00 OP